Confronto

Enfuvirtid vs. Octreotide

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

159519-65-0

83150-76-9

Peso molecolare

4491.88 g/mol

1019.24 g/mol

Emivita

nessun dato

1.7 h

Sequenza

nessun dato

D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)

Meccanismo d'azione

Enfuvirtid

Enfuvirtide binds the first heptad-repeat region (HR1) of the gp41 subunit of the HIV envelope protein. This prevents the conformational change required for fusion of the viral and cell membranes — the virus cannot enter the cell.

Octreotide

Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Enfuvirtid	Octreotide
Germania	Su prescrizione	Su prescrizione
Stati Uniti	Su prescrizione	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Enfuvirtid and Octreotide?: Enfuvirtid is classified as "Ricerca (altro)", while Octreotide is classified as "Ricerca (altro)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Enfuvirtid or Octreotide?: The highest available evidence level is "RCT sull'uomo" for Enfuvirtid and "RCT sull'uomo" for Octreotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Enfuvirtid and Octreotide in Germany and the United States?: Germania: Enfuvirtid — Su prescrizione, Octreotide — Su prescrizione. Stati Uniti: Enfuvirtid — Su prescrizione, Octreotide — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Enfuvirtid

Octreotide

Germania

Su prescrizione

Stati Uniti

Su prescrizione

Frequently asked questions

What is the difference between Enfuvirtid and Octreotide?

Enfuvirtid is classified as "Ricerca (altro)", while Octreotide is classified as "Ricerca (altro)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Enfuvirtid or Octreotide?

The highest available evidence level is "RCT sull'uomo" for Enfuvirtid and "RCT sull'uomo" for Octreotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Enfuvirtid and Octreotide in Germany and the United States?

Germania: Enfuvirtid — Su prescrizione, Octreotide — Su prescrizione. Stati Uniti: Enfuvirtid — Su prescrizione, Octreotide — Su prescrizione. These are factual summaries with source and review date on the individual pages.